Skip to main content

Table 3 Predictors of patients’ selection for breast conserving surgery, mastectomy, and axillary lymph node surgery

From: Revisit the practice of lymph node biopsy in patients diagnosed as ductal carcinoma in situ before operation: a retrospective analysis of 682 cases and evaluation of the role of breast MRI

 

Total mastectomy versus partial mastectomy (BCS)

Lymph node surgery versus no surgery

Pre-OP DCIS (N = 682)

Total mastectomy

N = 430

Partial mastectomy

N = 252

P value

No LN surgery

N = 62

With LN surgery

N = 620

P value

Age, year

51.9 ± 9.9

53.1 ± 10.5

0.14

54 ± 12.2

52.2 ± 9.9

0.17

Location

  

0.33

  

0.31

Right

213(49.5)

115(45.6)

 

26(41.9)

302(48.7)

 

Left

217(50.5)

137(54.4)

 

36(58.1)

318(51.3)

 

Biopsy method

N/A = 3

N/A = 0

 < 0.01

N/A = 0

N/A = 3

 < 0.01

CNB

298(69.8)

123(48.8)

 

19(30.6)

402(65.2)

 

Stereotactic biopsy

84(19.7)

83(32.9)

 

23(37.1)

144(23.3)

 

Excisional biopsy

43(10.1)

45(17.9)

 

18(29)

70(11.3)

 

MMG

2(0.5)

1(0.4)

 

2(3.2)

1(0.2)

 

Sonogram tumor size, cm

2.2 ± 1.2

1.6 ± 0.8

 < 0.01

1.7 ± 1.4

2 ± 1.1

0.11

Mammogram tumor size, cm

2.9 ± 1.3

2.0 ± 0.9

 < 0.01

1.6 ± 0.4

2.6 ± 1.2

0.10

MRI tumor size, cm

4.5 ± 2.3

2.8 ± 1.4

 < 0.01

2.7 ± 1.7

4 ± 2.2

 < 0.01

Pathology tumor sizea, cm (cm)

2.6 ± 2.9

1.7 ± 1.6

 < 0.01

1.8 ± 1.7

2.3 ± 2.6

0.22

Gross tumor size, cmb

(invasive + non-invasive)

4 ± 2.6

2.2 ± 1.4

 < 0.01

2.6 ± 1.8

3.5 ± 2.4

0.04

Stage

N/A = 11

N/A = 22

 < 0.01

N/A = 12

N/A = 21

0.03

0

226(53.9)

164(71.3)

 

40(80)

350(58.4)

 

I

130(31)

53(23)

 

8(16)

175(29.2)

 

II

54(12.9)

11(4.8)

 

2(4)

63(10.5)

 

III

9(2.1)

2(0.9)

 

0(0)

11(1.8)

 

Grade

N/A = 38

N/A = 36

 < 0.01

N/A = 19

N/A = 55

0.14

I

39(9.9)

37(17.1)

 

6(14.0)

70(12.4)

 

II

215(54.8)

122(56.5)

 

29(67.4)

308(54.5)

 

III

138(35.2)

57(26.4)

 

8(18.6)

187(33.1)

 

ER

N/A = 9

N/A = 15

 < 0.01

N/A = 11

N/A = 13

0.25

Positive

293(69.6)

191(80.6)

 

41(80.4)

443(73.0)

 

Negative

128(30.4)

46(19.4)

 

10(19.6)

164(27.0)

 

PR

N/A = 13

N/A = 20

 < 0.01

N/A = 11

N/A = 22

0.15

Positive

259(62.1)

179(77.2)

 

39(76.5)

399(66.7)

 

Negative

158(37.9)

53(22.8)

 

12(23.5)

199(33.3)

 

HER-2(N/A = 203)

N/A = 121

N/A = 82

0.53

N/A = 29

N/A = 174

0.64

Positive

118(38.2)

60(35.3)

 

11(33.3)

167(37.4)

 

Negative

191(61.8)

110(64.7)

 

22(66.7)

279(62.6)

 

Subtype

N/A = 68

N/A = 52

 < 0.01

N/A = 24

N/A = 96

0.17

Luminal A

198(54.7)

133(66.5)

 

27(71.1)

304(58.0)

 

Luminal B1

23(6.4)

11(5.5)

 

2(5.3)

32(6.1)

 

Luminal B2

50(13.8)

32(16.0)

 

7(18.4)

75(14.3)

 

HER-2( +)

56(15.5)

15(7.5)

 

2(5.3)

69(13.2)

 

TNBC

35(9.7)

9(4.5)

 

0(0)

44(8.4)

 

Post-OP pathology

  

 < 0.01

  

 < 0.01

DCIS

255(59.3)

194(77)

 

52(83.9)

397(64)

 

Upgrade

175(40.7)

58(23)

 

10(16.1)

223(36)

 

Ki-67

N/A = 313

N/A = 221

 < 0.01

N/A = 57

N/A = 477

0.92

≦ 20

67(57.3)

25(80.6)

 

3(60)

89(62.2)

 

 > 20

50(42.7)

6(19.4))

 

2(40)

54(37.8)

 

MRI LN metastasis

NA = 166

N/A = 109

 < 0.05

NA = 28

N/A = 247

0.10

Yes

69(26.1)

25(17.5)

 

30(88.2)

90(24.1)

 

No

195(73.9)

118(82.5)

 

4(11.8)

283(75.9)

 

Lymph node stage

N/A = 60

N/A = 23

 < 0.01

N/A = 15

N/A = 68

0.20

N0

327(88.4)

222(96.9)

 

47(100)

502(90.9)

 

N1

35(9.5)

5(2.2))

 

0(0)

40(7.2)

 

N2

6(1.6)

1(0.4)

 

0(0)

7(1.3)

 

N3

2(0.5)

1(0.4)

 

0(0)

3(0.5)

 

LN metastasis

N/A = 8

N/A = 25

 < 0.01

N/A = 29

N/A = 4

0.09

Yes

42(10)

7(3.1)

 

0(0)

49(8)

 

No

380(90)

220(96.9)

 

33(100)

567(92)

 

OP method

–

–

–

  

 < 0.01

Total

–

–

–

16(25.8)

414(66.8)

 

Partial

–

–

–

46(74.2)

206(33.2)

 

Method LN

  

 < 0.01

–

–

–

SLNB

350(81.4)

178(70.6)

 

–

–

–

SLNB + ALND

31(7.2)

18(7.1)

 

–

–

–

ALND

33(7.7)

10(4)

 

–

–

–

ND

16(3.7)

46(18.3)

 

–

–

–

  1. MMG mammography guided biopsy, LN lymph node, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, ND not done, OP operation, DCIS ductal carcinoma in situ, TNBC triple negative breast cancer, ER estrogen receptor, PR progesterone receptor, HER-2 human epithelial grow receptor type 2, N/A not available
  2. aPathology tumor size: in pure DCIS cases pathologic tumor size=DCIS tumor size, if containing invasive component then pathologic tumor size=invasive cancer tumor size
  3. bGross tumor size: invasive + non-invasive component tumor size